Tag: Bayer

Bayer
Healthcare
Germany

Valuation Analysis: Bayer AG

Bayer shows operational progress in the second quarter of 2026. Crop Science and new pharmaceutical products are strengthening the recovery,
Active icon
Continue Umbrella
Bayer
Healthcare
Germany

Stock: Bayer AG

Bayer is operationally improving its earnings position. However, high debt, weak cash flow, and legal risks are slowing the stock's
Active icon
Continue Umbrella
Weekly Update

Weekly Market Overview – August 10-August 16, 2026

TKMS raises its outlook, SpaceX is added to the UMBRELLA strategy, thereby strengthening its focus on defense, AI, and the
Continue Umbrella
Weekly Update

Weekly Market Overview – July 27-August 2, 2026

The market overview shows why strong figures from Apple, Rheinmetall, and other companies are not always enough for price gains.
Continue Umbrella
Weekly Update

Weekly Market Overview – July 20-26, 2026

Tesla is at the center of the earnings season following its Q2 results. The UMBRELLA Strategy is selling the position
Continue Umbrella
Weekly Update

Weekly Market Overview – July 13-19, 2026

IBM's earnings warning rattles the stock markets. Why fundamental data, quarterly results, and company outlooks are once again the most
Continue Umbrella
Thales
Company Update

Bayer Update: Roundup Hearing Moves into Focus

Bayer moves into focus ahead of the Roundup hearing. The stock approaches EUR 50 while legal risks and technical levels
Continue Umbrella
Bayer
Company Update

Bayer: Valuation Update After the Latest Price Recovery

Bayer after the latest price recovery: new developments in legal risks, analyst expectations, and the technical picture complement the valuation.
Continue Umbrella
MUMAK SpotLight

MUMAK SpotLight of the week: Intel becomes part of the UMBRELLA Strategy

Intel was newly added to the UMBRELLA Strategy, expanding the portfolio's semiconductor positioning. At the same time, Revolution Medicines, Bayer,
Continue Umbrella
Bayer
Company Update

Bayer – Q2 2026 Earnings Update

Bayer increases revenue and operating earnings in Q2 2026 and confirms its full-year targets despite legal risks.
Active icon
Continue Umbrella